MedTrace Logo

Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies

NCT04384393 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-01-11

No results posted yet for this study

Summary

This is a study to evaluate the safety and clinical activity of ThisCART19 (Allogeneic CAR-T targeting CD19) in patients with refractory or relapsed CD19 positive B cell malignancies.

Conditions

  • B Cell Malignancy

Interventions

BIOLOGICAL

ThisCART19 cells

0.2-60 x 10\^6 CAR T cells per kg body weight.

Sponsors & Collaborators

  • Anhui Provincial Hospital

    collaborator OTHER_GOV

  • Fundamenta Therapeutics, Ltd.

    lead INDUSTRY

Principal Investigators

  • Xingbing Wang · The First Affiliated Hospital of USTC (Anhui Provincial Hospital)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
3 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-09
Primary Completion
2022-11-10
Completion
2023-10-24

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04384393 on ClinicalTrials.gov